meso-2,3,4,5,6-O-pentabenzyl-scyllo-inositol | 22132-86-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: meso-2,3,4,5,6-O-pentabenzyl-scyllo-inositol
• 英文别名: 1,2,3,4,5-penta-O-benzyl scyllo-inositol；1,2,3,4,5-penta-O-benzyl-scyllo-inositol；2,3,4,5,6-Penta-O-benzyl-scyllo-inosit；1,3,4,5,6-Penta-O-benzyl-scyllo-inosit
• CAS: 22132-86-1
• 化学式: C₄₁H₄₂O₆
• 分子量: 630.781
• InChiKey: PLKAJAVHVAUNLR-QKYXCOEXSA-N

物化性质

• 沸点：
  732.7±60.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.29
• 重原子数：
  47.0
• 可旋转键数：
  15.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  66.38
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  meso-2,3,4,5,6-O-pentabenzyl-scyllo-inositol 在 二乙胺基三氟化硫 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以37%的产率得到1,3,4,5,6-Penta-O-benzyl-2-deoxy-2-fluoro-myo-inositol
  参考文献：
  名称：

  Synthesis of [3H]-labelled and unlabelled 2-deoxy-2-fluoro-myo-inositol and 1-deoxy-1-fluoro-scyllo-inositol for use in studies of the phosphoinositide cycle

  摘要：

  2-Deoxy-2-fluoro-myo-inositol and 1-deoxy-1-fluoro-scyllo-inositol have been synthesized in their unlabelled and tritiated forms in order to study their potential as inhibitors of the phosphoinositide cycle.

  DOI：

  10.1039/p19910001249
• 作为产物：
  描述：

  在 sodium hydride 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.67h， 生成 meso-2,3,4,5,6-O-pentabenzyl-scyllo-inositol
  参考文献：
  名称：

  The orientation of the β-hydroxyl group controls the diastereoselectivity during the hydride reduction and Grignard reaction of inososes

  摘要：

  A comparison of the results of the Grignard reaction and the hydride reduction of the carbonyl group of epi- and scyllo-inososes reveals that the extent of diastereoselectivity of these reactions is decided by the orientation of the beta-hydroxyl group (or its derivative). Presence of an axial beta-hydroxyl group generally results in the formation of relatively larger amount of the axial alcohol as a result of the reduction of the carbonyl group. The possible reasons for the observed differences in diastereoselectivity between the reactions of these isomeric epi- and scyllo-inososes have been discussed. The sequence of reactions reported here provides convenient access to C-allcylated inositols, such as iso-laminitol and iso-mytilitol as well as 2-O-methyl epi-inositol, an epimer of the naturally occurring ononitol. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.04.081

文献信息

• Diastereoselective synthesis of new O-alkylated and C-branched inositols and their corresponding fluoro analogues
  作者：Charlotte Collet、Françoise Chrétien、Yves Chapleur、Sandrine Lamandé-Langle

  DOI：10.3762/bjoc.12.39

  日期：——

  Efficient routes were developed for the diastereoselective synthesis of new O-alkylated and C-branched inositols and their corresponding fluoro analogues. The key steps of the synthesis were the easy accessibility of different types of arms in term of configuration (myo and scyllo), the linking method and length, which could modulate the biological properties. These inositol derivatives, bearing an

  为新的O-烷基化和C支化肌醇及其相应的氟类似物的非对映选择性合成开发了有效的途径。合成的关键步骤是在构型方面（myo和scyllo）易于接近不同类型的臂，连接方法和长度，这可以调节生物学特性。这些肌醇衍生物带有一个被羟基或氟原子封端的臂，可能是非对映异构中间体和生物学评估（尤其是PET成像实验）感兴趣的候选物。
• Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders
  申请人：Elmaleh David R.

  公开号：US20110060138A1

  公开（公告）日：2011-03-10

  One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

  本发明的一个方面涉及化合物、组合物和方法，用于诊断和/或治疗患有淀粉样变性相关病理状况的受试者。在某些实施例中，本发明的成像和/或治疗剂可以被注射给受试者，以便识别和/或治疗淀粉样沉积。一种特定的成像方法通过将成像剂注射给受试者并检测剂的空间分布来检测淀粉样沉积。剂的差异积累表明AD或淀粉样变性相关病理状况，并可以通过使用PET或SPECT相机进行监测。
• Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
  申请人：The General Hospital Corporation

  公开号：US10857247B2

  公开（公告）日：2020-12-08

  One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

  本发明的一个方面涉及用于诊断和/或治疗淀粉样变性相关病症的化合物、组合物和方法。在某些实施方案中，本发明的成像剂和/或治疗剂可用于受试者淀粉样蛋白沉积的鉴定和/或治疗。具体的成像方法是通过向受试者施用成像剂并检测成像剂的空间分布来检测淀粉样蛋白沉积。淀粉样蛋白沉积物的不同程度的积聚表明了多发性硬化症或与淀粉样蛋白沉积相关的病理状况，可使用 PET 或 SPECT 相机进行监测。
• [EN] COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LA DÉTECTION ET LE TRAITEMENT DE LA MALADIE D'ALZHEIMER ET DES TROUBLES ASSOCIÉS
  申请人：GEN HOSPITAL CORP

  公开号：WO2009117728A3

  公开（公告）日：2010-02-18
• Offer, John L.; Voorheis, H. Paul; Metcalfe, James C., Journal of the Chemical Society. Perkin transactions I, 1992, # 8, p. 953 - 960
  作者：Offer, John L.、Voorheis, H. Paul、Metcalfe, James C.、Smith, Gerry A.

  DOI：——

  日期：——